Thermo Fisher Scientific Inc Shares
Since the announcement of the idea, investors have already received a pre-tax return of 328% or an average annual return of 21.67%. Is it possible to expect such returns in the future? Based on today’s calculations, over a five to six-year perspective, one can expect an average annual stock price growth of 10%-17%. With dividends, the return may be slightly higher.
Nice buy at the right time!
Great news today! $PRED is going to be a beast. Uplist to Nasdaq next week!
PRED: Thermo Fisher Scientific and Predictive Laboratories Announce Global Infertility Research Collaboration
Good insightful read again from Goldman Sachs 34th Annual Global Healthcare Conference...
~ $TMO ~ Earnings posted, pending or coming soon! In Charts and Links Below!
~ $TMO ~ Earnings expected on Wednesday *
This Week In Earnings: Earnings are coming or are already posted! This is what the charts look like! If you play the earnings these posts can be very helpful to you!
Want more like this? Search Keyword: MACMONEY >>> http://tinyurl.com/MACMONEY <<<
One or more of many earnings sites has alerted this security has or will be posting earnings on or around the day of this message.
~ Barchart: http://barchart.com/quotes/stocks/TMO?
~ OTC Markets: http://www.otcmarkets.com/stock/TMO/company-info
~ Google Finance: http://www.google.com/finance?q=TMO
~ Google Fin Options: hhttp://www.google.com/finance/option_chain?q=TMO#
~ Yahoo! Finance ~ Stats: http://finance.yahoo.com/q/ks?s=TMO+Key+Statistics
~ Yahoo! Finance ~ Profile: http://finance.yahoo.com/q/pr?s=TMO
~ BusyStock: http://busystock.com/i.php?s=TMO&v=2
~ CandlestickChart: http://www.candlestickchart.com/cgi/chart.cgi?symbol=TMO&exchange=US
~ Investorshub Trades: http://ih.advfn.com/p.php?pid=trades&symbol=TMO
~ Investorshub Board Search: http://investorshub.advfn.com/boards/getboards.aspx?searchstr=TMO
~ Investorshub PostStream Search: http://investorshub.advfn.com/boards/poststream.aspx?ticker=TMO
~ Investorshub Goodies Search: http://investorshub.advfn.com/boards/msgsearchbyboard.aspx?boardID=18582&srchyr=2011&SearchStr=TMO
~ Investorshub Message Search: http://investorshub.advfn.com/boards/msgsearch.aspx?SearchStr=TMO
~ MarketWatch: http://www.marketwatch.com/investing/stock/TMO/profile
~ E-Zone Chart: http://www.windchart.com/ezone/signals/?symbol=TMO
~ 5-Min Wind: http://www.windchart.com/stockta/analysis?symbol=TMO
~ 10-Min Wind: http://www.windchart.com/stockta/analysis?symbol=TMO&size=l&frequency=10&color=g
~ 30-Min Wind: http://www.windchart.com/stockta/analysis?symbol=TMO&size=l&frequency=30&color=g
~ 60-Min Wind: http://www.windchart.com/stockta/analysis?symbol=TMO&size=l&frequency=60&color=g
*If the earnings date is in error please ignore error. I do my best.
For the week: +0.06%
Nice FDA approval. Look for strong steady increase in TMO. Also watch for ALRT. They expect their first FDA approval soon. Now only .09, should go to $1.00 or above upon approval.
My friends, for the week: -1%
Thermo Fisher Scientific to Acquire Dionex Corporation
Date : 12/13/2010 @ 7:00AM
Source : Business Wire
Stock : Thermo Fisher Scientific (TMO)
Thermo Fisher Scientific (NYSE: TMO), the world leader in serving science, and Dionex Corporation (NASDAQ: DNEX), a leading manufacturer and marketer of chromatography systems, today announced that their Boards of Directors have unanimously approved a transaction under which Thermo Fisher will acquire all of the outstanding shares of Dionex for $118.50 per share in cash, or a total purchase price of approximately $2.1 billion. The transaction is not conditioned on financing and is expected to be completed in the first quarter of 2011.
Under the terms of the agreement, Thermo Fisher will commence a tender offer to acquire all of the outstanding shares of Dionex common stock for $118.50 per share in cash. The consideration represents a 21% premium to Dionex’s closing stock price on December 10, 2010, the last trading day prior to today’s announcement and a 32% premium to Dionex’s average closing stock price over the last 60 trading days. Thermo Fisher expects to realize total operating synergies of $60 million in year three following the transaction’s close through a combination of cost savings and revenue enhancements. The transaction is expected to be immediately accretive to Thermo Fisher’s adjusted earnings per share by $0.13 to $0.15 in the first 12 months following the close. Adjusted earnings per share and adjusted operating income are non-GAAP measures that exclude certain items detailed later in this press release under the heading “Use of Non-GAAP Financial Measures.”
Dionex, based in Sunnyvale, Calif., introduced the first ion chromatography system for water analysis shortly after its founding in 1975 and has consistently grown through innovation and global expansion. Today, the company has more than 1,600 employees in 21 countries spanning six continents, including a significant presence in the Asia-Pacific region. Dionex will be integrated into Thermo Fisher’s Analytical Technologies Segment.
“We believe the combination of Thermo Fisher and Dionex is extremely compelling from a technology, market and financial perspective,” said Marc N. Casper, president and chief executive officer of Thermo Fisher. “Dionex’s strength in chromatography instruments, software and consumables complements our leading positions in mass spectrometry and laboratory information management systems. The transaction, which we expect to be immediately accretive, is consistent with our strategy of accelerating growth by increasing our depth of capabilities to serve attractive end markets. Specifically, it complements our strong presence in China, where we’ve established the headquarters for our global environmental instruments business and continue to build our commercial infrastructure to meet the needs of customers in growing water quality, consumer safety and life sciences markets.”
“We are pleased to be joining Thermo Fisher and are excited about the opportunities we will have as part of the world leader in serving science,” said Frank Witney, president and chief executive officer of Dionex. “Thermo Fisher’s commitment to innovation will fuel our ongoing technology development, and their global manufacturing and commercial presence will significantly strengthen our ability to deliver quality products and services to our customers around the world. This transaction offers immediate and significant value for our shareholders, as well as the opportunity for our customers and employees to benefit from combining two highly complementary organizations. We look forward to working closely with the Thermo Fisher team to ensure a smooth transition and complete the transaction as expeditiously as possible.”
Mr. Casper continued, “We are delighted to welcome Dionex’s talented and dedicated employees to our team. Together, we will offer our customers new solutions based on a powerful combination of leading instruments, software, consumables and services.”
Benefits of the Transaction
- Creates a Leading Chromatography Offering: The transaction brings two complementary chromatography portfolios together to create the most extensive chromatography instruments, software and consumables offering in the industry. Specifically, it combines Dionex’s ion and liquid chromatography systems and consumables with Thermo Fisher’s gas chromatography systems and consumables.
- Improves Performance and Productivity: Customers will benefit from the combination of Thermo Fisher’s leadership in mass spectrometry with Dionex’s comprehensive chromatography offering. By integrating these leading technologies and related software, Thermo Fisher will be able to deliver exceptional performance and productivity for customers through improved sample analysis and data management.
- Strengthens Software Growth Platform: Dionex’s gold standard chromatography data system coupled with Thermo Fisher’s leading enterprise laboratory information management systems creates the most comprehensive desktop and enterprise software capabilities in the industry. This combination will significantly improve performance, productivity and compliance for customers to maximize their return on investment.
- Expands Presence in Applied Markets: Thermo Fisher will benefit from Dionex’s significant customer base and relationships in attractive applied markets, including environmental analysis, food safety and other industrial sectors. Through this combination, Thermo Fisher will be able to deliver unmatched analytical solutions for a growing range of testing needs, particularly water analysis, where growth is driven by new regulatory requirements and increased testing in developing countries such as China.
- Increases Footprint in Asia-Pacific: Dionex currently generates more than 35% of its revenues in Asia-Pacific and other emerging high-growth geographies. The company has a history of growth in the region by establishing a strong reputation through its well-regarded direct sales and service presence there. This transaction is consistent with Thermo Fisher’s strategy of investing to increase its footprint in Asian markets, such as China and India, as well as other strategic growth markets, like Brazil.
- Offers Significant Synergies: The transaction is expected to generate a total of approximately $60 million of cost and revenue synergies in year three after the transaction’s close. This includes approximately $40 million from cost-related synergies and $20 million of adjusted operating income benefit from revenue-related synergies.
Mr. Casper concluded, “The acquisition of Dionex is another example of the great progress we’re making in executing on our strategy to accelerate growth. We have invested in technology innovation, Asia expansion and complementary acquisitions – all to strengthen our growth opportunities in attractive end markets. We are focused on these strategic investments because they create value for all our key stakeholders – customers, employees and shareholders.”
Financing and Approvals
Thermo Fisher intends to use cash on hand and proceeds from committed financing from Barclays Capital and J.P. Morgan Securities LLC to facilitate the transaction. The transaction, which is expected to be completed in the first quarter of 2011, is subject to the satisfaction of customary closing conditions, including applicable regulatory approvals.
Barclays Capital and J.P. Morgan Securities LLC are acting as financial advisors to Thermo Fisher, and Wachtell, Lipton, Rosen & Katz is serving as legal counsel. Goldman, Sachs & Co. is acting as financial advisor to Dionex, and Cooley LLP is serving as legal counsel.
Use of Non-GAAP Financial Measures
In addition to financial measures prepared in accordance with generally accepted accounting principles (GAAP), we use the non-GAAP financial measures adjusted operating income and adjusted earnings per share. Adjusted operating income excludes restructuring and other costs/income and amortization of acquisition-related intangible assets. Adjusted earnings per share also excludes certain other gains and losses, tax provisions/benefits related to the previous items, benefits from tax credit carryforwards, the impact of significant tax audits or events and discontinued operations. We exclude the above items because they are outside of our normal operations and/or, in certain cases, are difficult to forecast accurately for future periods. We believe that the use of non-GAAP measures helps investors to gain a better understanding of our core operating results and future prospects, consistent with how management measures and forecasts the company's performance, especially when comparing such results to previous periods or forecasts.
Conference Call and Webcast
Thermo Fisher and Dionex will host a conference call and Webcast at 8:30 a.m. EST today to provide more information on this announcement. The Webcast and accompanying slides can be accessed at www.thermofisher.com and www.dionex.com. An audio archive of the call will be available on both companies’ Websites until December 27, 2010, at 11:59 pm EST.
Conference Call Dial-in: Domestic: (866) 610-1072
International: (973) 935-2840
Replay Dial-in: Domestic: (800) 642-1687
International: (706) 645-9291
Since the wicked drop this summer, nothing but up!
And there was no follow through at all... as the market goes, so goes this stock.
Nice reversal in place on the daily...
60 days later, they caved but a nice reversal candle today...
The long term averages are acting as support...
Correcting/consolidating... we are watching.
Still going like the energizer bunny!
The weekly continues to reflect the strong intact uptrend.
Consolidating the last 2 months or so.
What a ride since the 20 buck low in November '08...
Moving back up after a little correction...
Capitulation took place and the march is on apparently...
The chart appears to be rolling over to the downside...
day trade this!!!!
News just released:
Thermo Fisher Scientific Acquires FIBERLite Centrifuge, Inc.
Acquisition Reinforces Thermo Fisher's Extensive Portfolio of Laboratory Centrifuge Rotors
WALTHAM, Mass.--(BUSINESS WIRE)--July 25, 2008--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that it has acquired FIBERLite Centrifuge, Inc., of Santa Clara, California. FIBERLite is the world's foremost supplier of carbon fiber centrifuge rotors, a strong and lightweight alternative that provides customers with a number of advantages over traditional metal rotors, including performance, safety, productivity and durability.
* The novelist George Eliot once said that "it is never too late to become what you might have been." That quote inspires me to seek those investments in the future that I didn't in the past.